# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY

E. Applicant: Biomedical Diagnostics (bmd) S.A.

F. Proprietary and Established Names: FIDIS™ Connective $1 0 ^ { * }$

# G. Regulatory Information:

1. Regulation section: 21CFR§ 866.5100, Antinuclear Antibody Immunological Test System   
2. Classification: Class II   
1. Product code: LLL, Extractable Antinuclear Antibody, Antigen, and Control LKJ, Antinuclear Antibody, Antigen, Control LKO, Anti-RNP Antibody, Antigen, Control LKP, Anti-Sm Antibody, Antigen, and Control LSW, Anti-DNA Antibody, Antigen and Control LJM, Antinuclear Antibody (Enzyme Labeled), Antigen, Controls MQA, Anti-Ribosomal P Antibodies

4. Panel: Immunology (82)

# H. Intended Use:

1. Intended use(s): The FIDIS ™ Connective $1 0 ^ { * }$ kit is a fluorescent immunoassay for the semiquantitative simultaneous detection of 10 autoantibody specificities directed against double stranded DNA (dsDNA), SSA ( $6 0 \mathrm { k D A }$ and $5 2 \mathrm { k D A } )$ ), SSB, Sm, Sm/RNP, Scl70, Jo-1 ribosome and centromere in human serum. (\*Antibodies to dsDNA, SSA, SSB, Sm, Sm/RNP, Scl-70, Jo-1, ribosome and centromere can be reported using this assay).

2. Indication(s) for use: The test system is used to screen serum samples and detect the presence of antinuclear antibodies associated with connective diseases systemic lupus erythematosus (SLE), Sjogren’s syndrome, mixed connective tissue disease (MCTD), scleroderma, dermatomyositis, and CREST syndrome, in conjunction with clinical findings and other laboratory tests.

3. Special conditions for use statement(s):

This device is for prescription use only.

4. Special instrument requirements: FIDIS™ Instrument (Luminex $\overline { { 2 0 0 } } ^ { \mathrm { T M } }$ plus FIDIS™ MLX-Booster 2.2Software) CARIS™ (Optional diluting and dispensing device)

# I. Device Description:

The device consists of the following: color-coded sets of microspheres (lyophilized). Each microsphere set is conjugated to one of the following antigens: dsDNA, SSa ( $6 0 \mathrm { k D A }$ and $5 2 \mathrm { k D A }$ ), SSB, Sm, Sm/RNP, Scl-70, Jo-1, ribosome and centromere; calibrator (ready to use); positive control (to be diluted); negative control (to be diluted); goat anti-human IgG conjugate coupled phycoerythrin (ready to use) and washing buffer (ready to use).

# J. Substantial Equivalence Information:

1. Predicate device name(s): FIDIS ™ Connective 10\*   
2. Predicate 510(k) number(s): k053653   
3. Comparison with predicate:

<table><tr><td rowspan=1 colspan=3>Similarities</td></tr><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>Device</td><td rowspan=1 colspan=1>Predicate</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Modified FIDISTM Connective 10*</td><td rowspan=1 colspan=1>Initial FIDISTM Connective 10*</td></tr><tr><td rowspan=1 colspan=1>Intended Use</td><td rowspan=1 colspan=1>Individual determination of IgGantibodies to dsDNA,SSA 60 kDA and 52 kDA, SSB, Sm,Sm/RNP, ScL-70, Jo-1, ribosomeand centromere</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Assay type</td><td rowspan=1 colspan=1>Flow cytometer based</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Assay format</td><td rowspan=1 colspan=1>Multiplexed</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Solid phasecapture</td><td rowspan=1 colspan=1>Color-coded microsphere</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Conjugate</td><td rowspan=1 colspan=1>Phycoerythin</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Sample type</td><td rowspan=1 colspan=1>Serum</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Type of test</td><td rowspan=1 colspan=1>Semi-quantitative</td><td rowspan=1 colspan=1>Same</td></tr></table>

<table><tr><td colspan="3" rowspan="1">Differences</td></tr><tr><td colspan="1" rowspan="1">Item</td><td colspan="1" rowspan="1">Modified FIDISTM Connective 10*</td><td colspan="1" rowspan="1">Initial FIDISTM Connective 10*</td></tr><tr><td colspan="1" rowspan="1">Materialsupplied</td><td colspan="1" rowspan="1">Microplate without caps</td><td colspan="1" rowspan="1">Microplate with caps</td></tr><tr><td colspan="1" rowspan="1">Beads</td><td colspan="1" rowspan="1">Vial of color-coded microsphere setLyophilized (sp 6mL)</td><td colspan="1" rowspan="1">6mL of vial of color-codedmicrosphere setready to use</td></tr><tr><td colspan="1" rowspan="1">SampleDilution</td><td colspan="1" rowspan="1">Sample dilution bufferready to use</td><td colspan="1" rowspan="1">PBS-Tween concentrated</td></tr><tr><td colspan="1" rowspan="1">Wash buffer</td><td colspan="1" rowspan="1">Sample dilution bufferready to use</td><td colspan="1" rowspan="1">PBS-Tween concentrated</td></tr><tr><td colspan="1" rowspan="1">Assayconfiguration</td><td colspan="1" rowspan="1">1 "reagent-blank" well1 "negative control" well</td><td colspan="1" rowspan="1">1 "reagent-blank" well1 "calibrator" well</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">1 "positive control" well2 "calibrator" wellsDiluted sample wells</td><td colspan="1" rowspan="1">1 "negative control" well1 "positive control" wellDiluted sample wellsA second calibrator well every32 well series</td></tr><tr><td colspan="1" rowspan="1">Assay protocol</td><td colspan="1" rowspan="1">Final wash step (not optional)</td><td colspan="1" rowspan="1">Optional final wash step</td></tr><tr><td colspan="1" rowspan="1">Software</td><td colspan="1" rowspan="1">Booster Version 2.2</td><td colspan="1" rowspan="1">Booster Version 1.35</td></tr><tr><td colspan="1" rowspan="1">Detection</td><td colspan="1" rowspan="1">Based on Luminex 200</td><td colspan="1" rowspan="1">Based on Luminex 100</td></tr></table>

# K. Standard/Guidance Document Referenced (if applicable):

CLSI C24A - Statistical Quality Control for Quantitative Measurement Procedures:   
Principles and Definitions   
CLSI M29A – Protection of Laboratory Workers from Occupationally Acquired   
Infection   
CLSI H18A –Procedures for the Handling and Processing of Blood Specimens

FIDIS™ CONNECTIVE $1 0 ^ { * }$ is based on the use of distinct uniform size colorcoded microspheres and a benchtop flow cytometer interfaced to a digital signal processing hardware and software. A red diode laser beam of the flow cytometer classifies each set of microspheres on the basis of its unique fluorescence intensity (red to orange) which allows to identify which analyte is being tested. At the same time, a green laser beam illuminates the external second molecule fluorescence to quantify the specific reaction related to each analyte.

Each antigen required for the assay is covalently coupled to an individual set of microspheres through its surface functional groups. The different antigen-coupled microspheres are mixed together to constitute the final microsphere reagent.

FIDIS™ CONNECTIVE $\mathbf { 1 0 ^ { * } }$ allows the detection of 10 autoantibody specificities: double stranded DNA (dsDNA), SSA $6 0 \mathrm { k D a }$ , SSA 52kDa, SSB, Sm, Sm/RNP, Scl70, Jo-1, Ribosomes and Centromeres. The microspheres are classified on the basis of their unique fluorescence intensity ratio that allows the identity of analyte being tested. Each dot in a white plot corresponds to an individual microsphere.

Seventy (70) $\mu \mathrm { L }$ of each sample are needed for each analysis. FIDIS™ Connective $1 0 ^ { * }$ assay was optimized by flow cytometry for the average binding capacity at the given dilution (1:200) from the median fluorescence value using 200 microspheres per parameter.

# M. Performance Characteristics (if/when applicable):

1. Analytical performance:

a. Precision/Reproducibility:

To evaluate intra-assay and inter assay reproducibility, four samples covering the reportable range of the assay were analyzed on the modified FIDIS™ Connective $1 0 ^ { * }$ . For within-run, the four samples were assayed 6 times in one run and for between-run; the four samples were assayed 2 times per run for 6 runs. Additional study was performed for dsDNA on the low end of the measuring range. Results

were as follows:

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=2>Within-run(10 tests in the same run)</td><td rowspan=1 colspan=2>Between-run(3 tests in 6 different runs)</td></tr><tr><td rowspan=1 colspan=1>Ahen</td><td rowspan=1 colspan=1>uanAae</td><td rowspan=1 colspan=1>(%) </td><td rowspan=1 colspan=1>Meanaae</td><td rowspan=1 colspan=1>(%) </td></tr><tr><td rowspan=6 colspan=1>dsDNA</td><td rowspan=1 colspan=1>496</td><td rowspan=1 colspan=1>5.9</td><td rowspan=1 colspan=1>508</td><td rowspan=1 colspan=1>10.5</td></tr><tr><td rowspan=1 colspan=1>87</td><td rowspan=1 colspan=1>6.1</td><td rowspan=1 colspan=1>104</td><td rowspan=1 colspan=1>13.8</td></tr><tr><td rowspan=1 colspan=1>63</td><td rowspan=1 colspan=1>8.9</td><td rowspan=1 colspan=1>63</td><td rowspan=1 colspan=1>6.7</td></tr><tr><td rowspan=1 colspan=1>52</td><td rowspan=1 colspan=1>8.0</td><td rowspan=1 colspan=1>64</td><td rowspan=1 colspan=1>12.6</td></tr><tr><td rowspan=1 colspan=1>14</td><td rowspan=1 colspan=1>8.2</td><td rowspan=1 colspan=1>14</td><td rowspan=1 colspan=1>10.8</td></tr><tr><td rowspan=1 colspan=1>12</td><td rowspan=1 colspan=1>8.6</td><td rowspan=1 colspan=1>14</td><td rowspan=1 colspan=1>8.3</td></tr><tr><td rowspan=4 colspan=1>SSA 60 kDa and52 kDa</td><td rowspan=1 colspan=1>209</td><td rowspan=1 colspan=1>2.1</td><td rowspan=1 colspan=1>202</td><td rowspan=1 colspan=1>5.4</td></tr><tr><td rowspan=1 colspan=1>81</td><td rowspan=1 colspan=1>7.8</td><td rowspan=1 colspan=1>81</td><td rowspan=1 colspan=1>4.5</td></tr><tr><td rowspan=1 colspan=1>64</td><td rowspan=1 colspan=1>5.3</td><td rowspan=1 colspan=1>64</td><td rowspan=1 colspan=1>5.5</td></tr><tr><td rowspan=1 colspan=1>19</td><td rowspan=1 colspan=1>11.2</td><td rowspan=1 colspan=1>23</td><td rowspan=1 colspan=1>8.8</td></tr><tr><td rowspan=4 colspan=1>SSB</td><td rowspan=1 colspan=1>192</td><td rowspan=1 colspan=1>2.6</td><td rowspan=1 colspan=1>176</td><td rowspan=1 colspan=1>8.8</td></tr><tr><td rowspan=1 colspan=1>74</td><td rowspan=1 colspan=1>8.0</td><td rowspan=1 colspan=1>76</td><td rowspan=1 colspan=1>7.0</td></tr><tr><td rowspan=1 colspan=1>26</td><td rowspan=1 colspan=1>5.2</td><td rowspan=1 colspan=1>25</td><td rowspan=1 colspan=1>14.6</td></tr><tr><td rowspan=1 colspan=1>19</td><td rowspan=1 colspan=1>2.5</td><td rowspan=1 colspan=1>18</td><td rowspan=1 colspan=1>10.9</td></tr><tr><td rowspan=4 colspan=1>Sm</td><td rowspan=1 colspan=1>306</td><td rowspan=1 colspan=1>3.2</td><td rowspan=1 colspan=1>303</td><td rowspan=1 colspan=1>6.8</td></tr><tr><td rowspan=1 colspan=1>81</td><td rowspan=1 colspan=1>9.1</td><td rowspan=1 colspan=1>87</td><td rowspan=1 colspan=1>9.4</td></tr><tr><td rowspan=1 colspan=1>66</td><td rowspan=1 colspan=1>8.6</td><td rowspan=1 colspan=1>63</td><td rowspan=1 colspan=1>10.8</td></tr><tr><td rowspan=1 colspan=1>49</td><td rowspan=1 colspan=1>12.7</td><td rowspan=1 colspan=1>48</td><td rowspan=1 colspan=1>12.7</td></tr><tr><td rowspan=4 colspan=1>Sm/RNP</td><td rowspan=1 colspan=1>236</td><td rowspan=1 colspan=1>8.4</td><td rowspan=1 colspan=1>236</td><td rowspan=1 colspan=1>9.3</td></tr><tr><td rowspan=1 colspan=1>133</td><td rowspan=1 colspan=1>7.9</td><td rowspan=1 colspan=1>139</td><td rowspan=1 colspan=1>7.6</td></tr><tr><td rowspan=1 colspan=1>92</td><td rowspan=1 colspan=1>11.5</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>14.3</td></tr><tr><td rowspan=1 colspan=1>75</td><td rowspan=1 colspan=1>6.2</td><td rowspan=1 colspan=1>70</td><td rowspan=1 colspan=1>9.5</td></tr><tr><td rowspan=4 colspan=1>Scl70</td><td rowspan=1 colspan=1>278</td><td rowspan=1 colspan=1>4.5</td><td rowspan=1 colspan=1>281</td><td rowspan=1 colspan=1>7.1</td></tr><tr><td rowspan=1 colspan=1>162</td><td rowspan=1 colspan=1>5.4</td><td rowspan=1 colspan=1>153</td><td rowspan=1 colspan=1>9.2</td></tr><tr><td rowspan=1 colspan=1>67</td><td rowspan=1 colspan=1>4.7</td><td rowspan=1 colspan=1>67</td><td rowspan=1 colspan=1>6.5</td></tr><tr><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>5.9</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>13.6</td></tr><tr><td rowspan=4 colspan=1>Jo1</td><td rowspan=1 colspan=1>282</td><td rowspan=1 colspan=1>9.7</td><td rowspan=1 colspan=1>268</td><td rowspan=1 colspan=1>9.7</td></tr><tr><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>3.0</td><td rowspan=1 colspan=1>92</td><td rowspan=1 colspan=1>9.4</td></tr><tr><td rowspan=1 colspan=1>57</td><td rowspan=1 colspan=1>7.7</td><td rowspan=1 colspan=1>65</td><td rowspan=1 colspan=1>11.5</td></tr><tr><td rowspan=1 colspan=1>9</td><td rowspan=1 colspan=1>12.8</td><td rowspan=1 colspan=1>9</td><td rowspan=1 colspan=1>12.2</td></tr><tr><td rowspan=4 colspan=1>Centromere</td><td rowspan=1 colspan=1>225</td><td rowspan=1 colspan=1>9.0</td><td rowspan=1 colspan=1>223</td><td rowspan=1 colspan=1>10.1</td></tr><tr><td rowspan=1 colspan=1>94</td><td rowspan=1 colspan=1>3.6</td><td rowspan=1 colspan=1>92</td><td rowspan=1 colspan=1>6.7</td></tr><tr><td rowspan=1 colspan=1>25</td><td rowspan=1 colspan=1>9.0</td><td rowspan=1 colspan=1>25</td><td rowspan=1 colspan=1>8.2</td></tr><tr><td rowspan=1 colspan=1>22</td><td rowspan=1 colspan=1>6.7</td><td rowspan=1 colspan=1>21</td><td rowspan=1 colspan=1>8.5</td></tr><tr><td rowspan=4 colspan=1>Ribosome</td><td rowspan=1 colspan=1>154</td><td rowspan=1 colspan=1>6.9</td><td rowspan=1 colspan=1>152</td><td rowspan=1 colspan=1>10.1</td></tr><tr><td rowspan=1 colspan=1>73</td><td rowspan=1 colspan=1>6.9</td><td rowspan=1 colspan=1>79</td><td rowspan=1 colspan=1>11.8</td></tr><tr><td rowspan=1 colspan=1>50</td><td rowspan=1 colspan=1>6.4</td><td rowspan=1 colspan=1>53</td><td rowspan=1 colspan=1>8.4</td></tr><tr><td rowspan=1 colspan=1>15</td><td rowspan=1 colspan=1>4.2</td><td rowspan=1 colspan=1>17</td><td rowspan=1 colspan=1>14.4</td></tr></table>

b. Linearity/assay reportable range:

Linearity is not claimed for this assay.

The dsDNA values in the calibrator are established using the WHO International Standard for anti-double stranded DNA (dsDNA), human code: WO/80. Other calibrator titers are expressed in arbitrary units per mL (AU/mL).

d. Detection limit: Not applicable

Interfering substances To evaluate the system for potential cross reactivity to other antibodies and interference from blood components, 30 samples were tested. High level of complement proteins were used but the specific kind of complement was not provided. A statement to avoid the use of abnormal concentration of these samples was added to the Limitations of the Procedure. The following results were obtained:

<table><tr><td rowspan=2 colspan=1></td><td rowspan=1 colspan=9>Number of Positive Samples</td></tr><tr><td rowspan=1 colspan=1>dsDNA</td><td rowspan=1 colspan=1>SSA 60/52kD</td><td rowspan=1 colspan=1>SSB</td><td rowspan=1 colspan=1>Sm</td><td rowspan=1 colspan=1>Sm/RNP</td><td rowspan=1 colspan=1>Scl70</td><td rowspan=1 colspan=1>Jo1</td><td rowspan=1 colspan=1>Centromere</td><td rowspan=1 colspan=1>Ribosome</td></tr><tr><td rowspan=1 colspan=1>Cryoglobulinemia (2)</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Complement (7)</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>IgG monoclonal Ig (1)</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>IgM monoclonal Ig (5)</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Rheumatoid Factor (8)</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>2/2</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Blood Plasma (3)</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Hemolyzed sera (3)</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Anti-smooth muscleantibodies (1)</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>→</td><td rowspan=1 colspan=1>→</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr></table>

f. Assay cut-off: Not applicable

2. Comparison studies:

a. Method comparison with predicate device: The tables below show the comparison of serum samples $\scriptstyle ( \mathrm { N } = 2 6 4$ ) that were tested with the Modified FIDIS™ Connective $1 0 ^ { * }$ and the predicate device (Initial FIDIS™ Connective $1 0 ^ { * }$ ). No information about age, gender, and clinical status was provided.

194 positive samples for one or more parameters related to systemic   
autoimmune diseases   
70 negative samples

All borderline results with the two devices were considered negative.

<table><tr><td rowspan=2 colspan=2></td><td rowspan=1 colspan=3>Initial FIDISTM Connective 10* dsDNA</td></tr><tr><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=3 colspan=1>Modified FIDISTMConnective 10*dsDNA</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>45</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>46</td></tr><tr><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>66</td><td rowspan=1 colspan=1>70</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>49</td><td rowspan=1 colspan=1>67</td><td rowspan=1 colspan=1>116</td></tr></table>

Positive $\%$ agreement: $9 1 . 8 4 \%$ $( 9 5 \% \mathsf { C l } ; 8 4 . 2 \% - 9 9 . 5 \% )$

Negative $\%$ agreement: $9 8 . 5 1 \%$ $9 5 \%$ CI: 95.6% - 100%) Overall $\%$ agreement: $9 5 . 6 9 \%$ $9 5 \%$ CI: 92.0% - 99.4%)

<table><tr><td rowspan=2 colspan=2></td><td rowspan=1 colspan=3>Initial FIDISTM Connective 10*SSA 60/kDa</td></tr><tr><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=3 colspan=1>Modified FIDISTMConnective 10*SSA 60/kDa</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>48</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>49</td></tr><tr><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>69</td><td rowspan=1 colspan=1>70</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>48</td><td rowspan=1 colspan=1>70</td><td rowspan=1 colspan=1>119</td></tr></table>

Positive $\%$ agreement: $100 \%$ Negative $\%$ agreement: $9 8 . 5 7 \%$ $9 5 \%$ CI: $9 5 . 8 \% - 1 0 0 \%$ ) Overall $\%$ agreement: $9 9 . 1 5 \%$ $9 5 \%$ CI: 97.52% - 100%)

<table><tr><td rowspan=2 colspan=2></td><td rowspan=1 colspan=3>Initial FIDISTM Connective 10*SSA 52kDa</td></tr><tr><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=3 colspan=1>Modified FIDISTMConnective 10*SSA 52kDa</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>58</td><td rowspan=1 colspan=1>2</td><td rowspan=2 colspan=1>6067</td></tr><tr><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>64</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>61</td><td rowspan=1 colspan=1>66</td><td rowspan=1 colspan=1>127</td></tr></table>

Positive $\%$ agreement: $9 5 . 0 8 \%$ (95% CI: 89.7%, $- 1 0 0 . 0 \% )$ Negative $\%$ agreement: 96.97% (95% CI: 92.8 – 100%) Overall $\%$ agreement: $9 6 . 0 6 \%$ (95% CI: 92.7% -99.4%)

<table><tr><td rowspan=2 colspan=2></td><td rowspan=1 colspan=3>Initial FIDISTM Connective 10* SSB</td></tr><tr><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=3 colspan=1>Modified FIDISTMConnective 10*SSB</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>23</td><td rowspan=1 colspan=1>2</td><td rowspan=2 colspan=1>2568</td></tr><tr><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>68</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>23</td><td rowspan=1 colspan=1>70</td><td rowspan=1 colspan=1>93</td></tr></table>

Positive $\%$ agreement: $100 \%$ Negative $\%$ agreement: $9 7 . 1 4 \%$ (95%CI: 93.2% - 100%) Overall $\%$ agreement: $9 7 . 8 5 \%$ $9 5 \%$ CI: 94.9% - 100%)

<table><tr><td rowspan=2 colspan=2></td><td rowspan=1 colspan=3>Initial FIDISTM Connective 10* Sm</td></tr><tr><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=3 colspan=1>Modified FIDISTMConnective 10* Sm</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>23</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>25</td></tr><tr><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>73</td><td rowspan=1 colspan=1>74</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>24</td><td rowspan=1 colspan=1>75</td><td rowspan=1 colspan=1>99</td></tr></table>

Positive $\%$ agreement: $9 5 . 8 3 \%$ (95% CI: 87.8% - 100%) Negative $\%$ agreement: 97.33% (95%CI: 93.7% - 100%) Overall $\%$ agreement: 96.97% (95% CI: 93.6%- 100%)

<table><tr><td rowspan=2 colspan=2></td><td rowspan=1 colspan=3>Initial FIDISTM Connective 10* Sm/RNP</td></tr><tr><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=3 colspan=1>Modified FIDISTMConnective 10*Sm/RNP</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>31</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>33</td></tr><tr><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>76</td><td rowspan=1 colspan=1>77</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>32</td><td rowspan=1 colspan=1>78</td><td rowspan=1 colspan=1>110</td></tr></table>

Positive $\%$ agreement: Negative $\%$ agreement: Overall $\%$ agreement:

$9 6 . 8 8 \%$ $9 5 \%$ CI: 90.8% - 100%) $9 7 . 4 4 \%$ (95%CI: 93.9% - 100%) $9 7 . 2 7 \%$ $9 5 \%$ CI: 94.2% - 100%)

<table><tr><td rowspan=2 colspan=2></td><td rowspan=1 colspan=3>Initial FIDISTMConnective 10* Scl70</td></tr><tr><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=3 colspan=1>Modified FIDIS™Connective 10*Scl70</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>27</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>29</td></tr><tr><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>68</td><td rowspan=1 colspan=1>69</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>28</td><td rowspan=1 colspan=1>70</td><td rowspan=1 colspan=1>98</td></tr></table>

Positive $\%$ agreement: $9 6 . 4 3 \%$ $( 9 5 \% 0 \mathsf { C l } \colon 8 9 . 2 \% 1 0 0 \% )$ Negative $\%$ agreement: 97.14% (95%CI: 93.2% - 100%) Overall $\%$ agreement: 96.94% (95% CI: 93.5% - 100%)

<table><tr><td rowspan=2 colspan=2></td><td rowspan=1 colspan=3>Initial FIDISTM Connective 10* Jo1</td></tr><tr><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=3 colspan=1>Modified FIDISTMConnective 10*Jo1</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>26</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>26</td></tr><tr><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>69</td><td rowspan=1 colspan=1>70</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>27</td><td rowspan=1 colspan=1>69</td><td rowspan=1 colspan=1>96</td></tr></table>

Positive $\%$ agreement: $9 6 . 3 \%$ (95%CI: 89.2% - 100.0% Negative $\%$ agreement: $100 \%$ Overall $\%$ agreement: 98.96% $9 5 \%$ CI: 96.9% - 100%)

<table><tr><td rowspan=2 colspan=2></td><td rowspan=1 colspan=3>Initial FIDISTM Connective 10* Centromere</td></tr><tr><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=3 colspan=1>Modified FIDISTMConnective 10*Centromere</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>20</td></tr><tr><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>69</td><td rowspan=1 colspan=1>69</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>69</td><td rowspan=1 colspan=1>89</td></tr></table>

Positive $\%$ agreement: $8 3 . 3 3 \%$ $( 9 5 \% 0 0 ! ; 6 8 . 4 \% - 9 8 . 2 \% )$ Negative $\%$ agreement: $100 \%$ Overall $\%$ agreement: 95.83% (95% CI: 91.8% - 99.8%)

<table><tr><td rowspan=2 colspan=2></td><td rowspan=1 colspan=3>Initial FIDISTM Connective 10* Ribosome</td></tr><tr><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=3 colspan=1>Modified FIDISTMConnective 10*Ribosome</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>18</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>18</td></tr><tr><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>69</td><td rowspan=1 colspan=1>69</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>18</td><td rowspan=1 colspan=1>69</td><td rowspan=1 colspan=1>87</td></tr></table>

Positive $\%$ agreement: $100 \%$ Negative $\%$ agreement: $100 \%$ Overall $\%$ agreement: 100%

# Comparison of the automated CARIS system and manual method

A comparison study between the manual method and the automated CARIS™ system was also performed. All borderline results with the two methods were considered negative.

<table><tr><td rowspan=2 colspan=2>dsDNA</td><td rowspan=1 colspan=3>Manual FIDIS</td></tr><tr><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=3 colspan=1>CarisFIDIS</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>43</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>43</td></tr><tr><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>69</td><td rowspan=1 colspan=1>69</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>43</td><td rowspan=1 colspan=1>69</td><td rowspan=1 colspan=1>112</td></tr></table>

Positive $\%$ agreement: 100.0% Negative $\%$ agreement: 100.0% Overall $\%$ agreement: 100.0%

<table><tr><td rowspan=2 colspan=2>SSA (60kDa)</td><td rowspan=1 colspan=3>Manual FIDIS</td></tr><tr><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=3 colspan=1>CarisFIDIS</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>42</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>42</td></tr><tr><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>68</td><td rowspan=1 colspan=1>68</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>42</td><td rowspan=1 colspan=1>68</td><td rowspan=1 colspan=1>110</td></tr></table>

Positive $\%$ agreement: 100.0% Negative $\%$ agreement: 100.0% Overall $\%$ agreement: 100.0%

<table><tr><td rowspan=2 colspan=2>SSA (52kDa)</td><td rowspan=1 colspan=3>Manual FIDIS</td></tr><tr><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=3 colspan=1>CarisFIDIS</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>52</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>53</td></tr><tr><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>65</td><td rowspan=1 colspan=1>65</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>52</td><td rowspan=1 colspan=1>66</td><td rowspan=1 colspan=1>118</td></tr></table>

Positive $\%$ agreement: $1 0 0 . 0 \%$ Negative $\%$ agreement: $9 8 . 5 \%$ Overall $\%$ agreement: 99.2%

<table><tr><td rowspan=2 colspan=2>SSB</td><td rowspan=1 colspan=3>Manual FIDIS</td></tr><tr><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=3 colspan=1>CarisFIDIS</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>25</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>25</td></tr><tr><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>67</td><td rowspan=1 colspan=1>67</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>25</td><td rowspan=1 colspan=1>67</td><td rowspan=1 colspan=1>92</td></tr></table>

Positive $\%$ agreement: $1 0 0 . 0 \%$ Negative $\%$ agreement: 100.0% Overall $\%$ agreement: 100.0%

<table><tr><td rowspan=2 colspan=2>Sm</td><td rowspan=1 colspan=3>Manual FIDIS</td></tr><tr><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=3 colspan=1>CarisFIDIS</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>24</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>27</td></tr><tr><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>69</td><td rowspan=1 colspan=1>69</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>24</td><td rowspan=1 colspan=1>72</td><td rowspan=1 colspan=1>96</td></tr></table>

Positive $\%$ agreement: $1 0 0 . 0 \%$ Negative $\%$ agreement: $9 5 . 8 \%$ Overall $\%$ agreement: $9 6 . 9 \%$

<table><tr><td rowspan=2 colspan=2>Sm/RNP</td><td rowspan=1 colspan=3>Manual FIDIS</td></tr><tr><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=3 colspan=1>CarisFIDIS</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>32</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>35</td></tr><tr><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>68</td><td rowspan=1 colspan=1>68</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>32</td><td rowspan=1 colspan=1>71</td><td rowspan=1 colspan=1>103</td></tr></table>

Positive $\%$ agreement: $1 0 0 . 0 \%$ Negative $\%$ agreement: 95.8% Overall $\%$ agreement: 97.1%

<table><tr><td rowspan=2 colspan=2>Scl70</td><td rowspan=1 colspan=3>Manual FIDIS</td></tr><tr><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=3 colspan=1>CarisFIDIS</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>29</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>29</td></tr><tr><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>68</td><td rowspan=1 colspan=1>68</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>29</td><td rowspan=1 colspan=1>68</td><td rowspan=1 colspan=1>97</td></tr></table>

Positive $\%$ agreement: 100.0% Negative $\%$ agreement: 100.0% Overall $\%$ agreement: 100.0%

<table><tr><td rowspan=2 colspan=2>Jo1</td><td rowspan=1 colspan=3>Manual FIDIS</td></tr><tr><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=3 colspan=1>CarisFIDIS</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>26</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>26</td></tr><tr><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>69</td><td rowspan=1 colspan=1>69</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>26</td><td rowspan=1 colspan=1>69</td><td rowspan=1 colspan=1>112</td></tr></table>

Positive $\%$ agreement: 100.0% Negative $\%$ agreement: 100.0% Overall $\%$ agreement: 100.0% b. Matrix comparison: Serum is the only recommended matrix.

<table><tr><td rowspan=2 colspan=2>Centromere</td><td rowspan=1 colspan=3>Manual FIDIS</td></tr><tr><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=3 colspan=1>CarisFIDIS</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>24</td></tr><tr><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>69</td><td rowspan=1 colspan=1>69</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>73</td><td rowspan=1 colspan=1>93</td></tr></table>

Positive $\%$ agreement: $1 0 0 . 0 \%$ Negative $\%$ agreement: $9 4 . 5 \%$ Overall $\%$ agreement: 95.7%

<table><tr><td rowspan=2 colspan=2>Ribosome</td><td rowspan=1 colspan=3>Manual FIDIS</td></tr><tr><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=3 colspan=1>CarisFIDIS</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>8</td></tr><tr><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>68</td><td rowspan=1 colspan=1>68</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>68</td><td rowspan=1 colspan=1>78</td></tr></table>

Positive $\%$ agreement: $1 0 0 . 0 \%$ Negative $\%$ agreement: 100.0% Overall $\%$ agreement: $1 0 0 . 0 \%$

3. Clinical studies: a. Clinical Sensitivity: Not provided b. Clinical specificity: Not provided c. Other clinical supportive data (when a. and b. are not applicable): Not applicable

4. Clinical cut-off:

Not applicable

5. Expected values/Reference range:

The reported expected ranges were estimated from 2 populations:

50 samples from blood donors   
48 samples selected from their potential biological interferences and according to WHO standard for dsDNA specificity

<table><tr><td rowspan=1 colspan=1>Arbitrary units (AU/mL)</td><td rowspan=1 colspan=1>&lt;30AU/mL</td><td rowspan=1 colspan=1>30-40AU/mL</td><td rowspan=1 colspan=1>&gt;40AU/mL</td></tr><tr><td rowspan=1 colspan=1>International units (IU/mL)For dsDNA</td><td rowspan=1 colspan=1>&lt;30IU/mL</td><td rowspan=1 colspan=1>30-40IU/mL</td><td rowspan=1 colspan=1>&gt;40IU/mL</td></tr><tr><td rowspan=1 colspan=1>Interpretation</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Equivocal</td><td rowspan=1 colspan=1>Positive</td></tr></table>

The negative thresholds $( 3 0 \mathrm { A U / m L }$ or $3 0 \mathrm { I U / m L }$ ) correspond to the $9 7 . 9 ^ { \mathrm { t h } }$ percentile for dsDNA, SSA, $\operatorname { S m } / \operatorname { R N P }$ ; $9 9 . 0 \%$ for centromere and ribosome, and $100 \%$ for SSB, Sm, Scl70 and Jo1 for the populations studied.

# N. Proposed Labeling:

The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.

# O. Conclusion:

The submitted information in this premarket notification is complete and supports a substantial equivalence decision.